{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:13:43Z","timestamp":1791684823599,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tonix Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"DOI":"10.1007\/s10875-026-02028-8","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:37:06Z","timestamp":1777437426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy Adults"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2781-1455","authenticated-orcid":false,"given":"Seth","family":"Lederman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2875-3920","authenticated-orcid":false,"given":"Bruce L.","family":"Daugherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6726-1483","authenticated-orcid":false,"given":"Nancy","family":"Herje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1707-4490","authenticated-orcid":false,"given":"Gregory M.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"4","key":"2028_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1084\/jem.175.4.1091","volume":"175","author":"S Lederman","year":"1992","unstructured":"Lederman S, Yellin MJ, Krichevsky A, et al. Identification of a novel surface protein on activated CD4\u2009+\u2009T cells that induces contact-dependent B cell differentiation (help). J Exp Med. 1992;175(4):1091\u2013101.","journal-title":"J Exp Med"},{"issue":"6373","key":"2028_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/357080a0","volume":"357","author":"RJ Armitage","year":"1992","unstructured":"Armitage RJ, Fanslow WC, Strockbine L, et al. Molecular and biological characterization of a murine ligand for CD40. Nature. 1992;357(6373):80\u20132.","journal-title":"Nature"},{"issue":"12","key":"2028_CR3","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0969-2126(01)00278-7","volume":"3","author":"M Karpusas","year":"1995","unstructured":"Karpusas M, Hsu YM, Wang JH, et al. 2 A crystal structure of an extracellular fragment of human CD40 ligand. Structure. 1995;3(12):1426.","journal-title":"Structure"},{"issue":"14","key":"2028_CR4","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1073\/pnas.89.14.6550","volume":"89","author":"RJ Noelle","year":"1992","unstructured":"Noelle RJ, Roy M, Shepherd DM, et al. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A. 1992;89(14):6550\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2028_CR5","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.4049\/jimmunol.149.12.3817","volume":"149","author":"S Lederman","year":"1992","unstructured":"Lederman S, Yellin MJ, Inghirami G, et al. Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help. J Immunol. 1992;149(12):3817\u201326.","journal-title":"J Immunol"},{"issue":"5","key":"2028_CR6","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.4049\/jimmunol.152.5.2163","volume":"152","author":"S Lederman","year":"1994","unstructured":"Lederman S, Yellin MJ, Cleary AM, et al. T-BAM\/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death. J Immunol. 1994;152(5):2163\u201371.","journal-title":"J Immunol"},{"issue":"11","key":"2028_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/0167-5699(93)90188-Q","volume":"14","author":"RE Callard","year":"1993","unstructured":"Callard RE, Armitage RJ, Fanslow WC, Spriggs MK. CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol Today. 1993;14(11):559\u201364.","journal-title":"Immunol Today"},{"issue":"6","key":"2028_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/0161-5890(94)90066-3","volume":"31","author":"LR Covey","year":"1994","unstructured":"Covey LR, Cleary AM, Yellin MJ, et al. Isolation of cDNAs encoding T-BAM, a surface glycoprotein on CD4\u2009+\u2009T cells mediating contact-dependent helper function for B cells: identity with the CD40-ligand. Mol Immunol. 1994;31(6):471\u201384.","journal-title":"Mol Immunol"},{"issue":"7","key":"2028_CR9","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.4049\/jimmunol.155.7.3329","volume":"155","author":"AM Cleary","year":"1995","unstructured":"Cleary AM, Fortune SM, Yellin MJ, Chess L, Lederman S. Opposing roles of CD95 (Fas\/APO-1) and CD40 in the death and rescue of human low density tonsillar B cells. J Immunol. 1995;155(7):3329\u201337.","journal-title":"J Immunol"},{"issue":"11","key":"2028_CR10","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1097\/00007890-199912150-00026","volume":"68","author":"RN 3rd Pierson","year":"1999","unstructured":"Pierson RN 3rd, Chang AC, Blum MG, et al. Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody. Transplantation. 1999;68(11):1800\u20135.","journal-title":"Transplantation"},{"issue":"6","key":"2028_CR11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/9536","volume":"5","author":"AD Kirk","year":"1999","unstructured":"Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med. 1999;5(6):686\u201393.","journal-title":"Nat Med"},{"issue":"3","key":"2028_CR12","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/art.10856","volume":"48","author":"DT Boumpas","year":"2003","unstructured":"Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48(3):719\u201327.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2028_CR13","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1002\/art.10273","volume":"46","author":"W Huang","year":"2002","unstructured":"Huang W, Sinha J, Newman J, et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. 2002;46(6):1554\u201362.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2028_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/xen.12166","volume":"22","author":"L Higginbotham","year":"2015","unstructured":"Higginbotham L, Mathews D, Breeden CA, et al. Pre-transplant antibody screening and anti-CD154 costimulation blockade promote long-term xenograft survival in a pig-to-primate kidney transplant model. Xenotransplantation. 2015;22(3):221\u201330.","journal-title":"Xenotransplantation"},{"issue":"7736","key":"2028_CR15","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-018-0765-z","volume":"564","author":"M Langin","year":"2018","unstructured":"Langin M, Mayr T, Reichart B, et al. Consistent success in life-supporting porcine cardiac xenotransplantation. Nature. 2018;564(7736):430\u20133.","journal-title":"Nature"},{"issue":"1","key":"2028_CR16","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/s41598-018-20566-z","volume":"8","author":"EW Choi","year":"2018","unstructured":"Choi EW, Lee KW, Park H, et al. Therapeutic effects of anti-CD154 antibody in cynomolgus monkeys with advanced rheumatoid arthritis. Sci Rep. 2018;8(1):2135.","journal-title":"Sci Rep"},{"issue":"489","key":"2028_CR17","doi-asserted-by":"publisher","first-page":"eaar6584","DOI":"10.1126\/scitranslmed.aar6584","volume":"11","author":"JL Karnell","year":"2019","unstructured":"Karnell JL, Albulescu M, Drabic S, et al. A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity. Sci Transl Med. 2019;11(489):eaar6584.","journal-title":"Sci Transl Med"},{"issue":"11","key":"2028_CR18","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","volume":"60","author":"RA Furie","year":"2021","unstructured":"Furie RA, Bruce IN, Dorner T, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(11):5397\u2013407.","journal-title":"Rheumatology (Oxford)"},{"issue":"7982","key":"2028_CR19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41586-023-06594-4","volume":"622","author":"RP Anand","year":"2023","unstructured":"Anand RP, Layer JV, Heja D, et al. Design and testing of a humanized porcine donor for xenotransplantation. Nature. 2023;622(7982):393\u2013401.","journal-title":"Nature"},{"issue":"8","key":"2028_CR20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.ajt.2023.03.022","volume":"23","author":"G Lassiter","year":"2023","unstructured":"Lassiter G, Otsuka R, Hirose T, et al. TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate renal allograft survival. Am J Transpl. 2023;23(8):1171\u201381.","journal-title":"Am J Transpl"},{"issue":"8","key":"2028_CR21","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.ajt.2023.03.025","volume":"23","author":"S Miura","year":"2023","unstructured":"Miura S, Habibabady ZA, Pollok F, et al. TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival. Am J Transpl. 2023;23(8):1182\u201393.","journal-title":"Am J Transpl"},{"issue":"711","key":"2028_CR22","doi-asserted-by":"publisher","first-page":"eadf6376","DOI":"10.1126\/scitranslmed.adf6376","volume":"15","author":"IJ Anwar","year":"2023","unstructured":"Anwar IJ, Berman DM, DeLaura I, et al. The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates. Sci Transl Med. 2023;15(711):eadf6376.","journal-title":"Sci Transl Med"},{"issue":"7","key":"2028_CR23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2309439","volume":"390","author":"P Vermersch","year":"2024","unstructured":"Vermersch P, Granziera C, Mao-Draayer Y, et al. Inhibition of CD40L with frexalimab in multiple sclerosis. N Engl J Med. 2024;390(7):589\u2013600.","journal-title":"N Engl J Med"},{"issue":"2","key":"2028_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/72162","volume":"6","author":"T Kawai","year":"2000","unstructured":"Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6(2):114.","journal-title":"Nat Med"},{"issue":"9","key":"2028_CR25","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1161\/01.RES.0000070111.98158.6C","volume":"92","author":"DP Inwald","year":"2003","unstructured":"Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res. 2003;92(9):1041\u20138.","journal-title":"Circ Res"},{"issue":"3","key":"2028_CR26","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.4049\/jimmunol.0903888","volume":"185","author":"L Robles-Carrillo","year":"2010","unstructured":"Robles-Carrillo L, Meyer T, Hatfield M, et al. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol. 2010;185(3):1577\u201383.","journal-title":"J Immunol"},{"issue":"11","key":"2028_CR27","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1093\/intimm\/dxh162","volume":"16","author":"JL Ferrant","year":"2004","unstructured":"Ferrant JL, Benjamin CD, Cutler AH, et al. The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. Int Immunol. 2004;16(11):1583\u201394.","journal-title":"Int Immunol"},{"issue":"9","key":"2028_CR28","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.4049\/jimmunol.1303239","volume":"192","author":"JH Xie","year":"2014","unstructured":"Xie JH, Yamniuk AP, Borowski V, et al. Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases. J Immunol. 2014;192(9):4083\u201392.","journal-title":"J Immunol"},{"issue":"1","key":"2028_CR29","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13075-015-0757-4","volume":"17","author":"A Shock","year":"2015","unstructured":"Shock A, Burkly L, Wakefield I, et al. CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther. 2015;17(1):234.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"2028_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0969-2126(01)00590-1","volume":"9","author":"M Karpusas","year":"2001","unstructured":"Karpusas M, Lucci J, Ferrant J, et al. Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody. Structure. 2001;9(4):321\u20139.","journal-title":"Structure"},{"issue":"3","key":"2028_CR31","first-page":"3607","volume":"8","author":"X Li","year":"2015","unstructured":"Li X, Hu P, Yang R, et al. A noncytolytic antibody-like extendin-4-IgG4 fusion protein as a long-acting potential anti-diabetic agent. Int J Clin Exp Med. 2015;8(3):3607\u201318.","journal-title":"Int J Clin Exp Med"},{"issue":"4","key":"2028_CR32","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.4049\/jimmunol.164.4.1925","volume":"164","author":"MP Reddy","year":"2000","unstructured":"Reddy MP, Kinney CA, Chaikin MA, et al. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol. 2000;164(4):1925\u201333.","journal-title":"J Immunol"},{"issue":"1","key":"2028_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1006\/cimm.2000.1617","volume":"200","author":"D Xu","year":"2000","unstructured":"Xu D, Alegre ML, Varga SS, et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 2000;200(1):16\u201326.","journal-title":"Cell Immunol"},{"key":"2028_CR34","doi-asserted-by":"publisher","first-page":"100288","DOI":"10.1016\/j.jtauto.2025.100288","volume":"10","author":"M Mabrouk","year":"2025","unstructured":"Mabrouk M, Wahnou H, Merhi Y, et al. The role of soluble CD40L in autoimmune diseases. J Translational Autoimmun. 2025;10:100288.","journal-title":"J Translational Autoimmun"},{"key":"2028_CR35","doi-asserted-by":"crossref","unstructured":"Fadul CE, Mao-Draayer Y, Ryan KA et al. Safety and immune effects of blocking CD40 ligand in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2021;8(6):e1096.","DOI":"10.1212\/NXI.0000000000001096"},{"key":"2028_CR36","doi-asserted-by":"crossref","unstructured":"Veerasubramanian PK, Wynn TA, Quan J, Karlsson FJ. Targeting TNF\/TNFR superfamilies in immune-mediated inflammatory diseases. J Exp Med 2024;221(11):e20240806.","DOI":"10.1084\/jem.20240806"},{"key":"2028_CR37","first-page":"A1","volume":"2017\/011544","author":"J Rothstein","year":"2017","unstructured":"Rothstein J, Holgate RGE, Hearn A, Inventors. Anti-CD154 antibody having improved binding, functional, and safety characteristics and use in human immunotherapy. US patent WO. 2017;2017\/011544:A1.","journal-title":"US patent WO"},{"issue":"9","key":"2028_CR38","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1097\/TP.0000000000001836","volume":"101","author":"NA O\u2019Neill","year":"2017","unstructured":"O\u2019Neill NA, Zhang T, Braileanu G, et al. Comparative evaluation of \u03b1CD40 (2C10R4) and \u03b1CD154 (5C8H1 and IDEC-131) in a nonhuman primate cardiac allotransplant model. Transplantation. 2017;101(9):2038\u201347.","journal-title":"Transplantation"},{"key":"2028_CR39","unstructured":"World Health Organization. WHO Drug Information: International Nonproprietary Names for Pharmaceutical Substances. Vol 36(4). Geneva; 2022."},{"key":"2028_CR40","unstructured":"U.S, Food, Drug Administration. &. FDA\u2019s Global Substance Registration System - Tegoprubart. U.S. Food & Drug Administration. Available at: https:\/\/precision.fda.gov\/uniisearch\/srs\/unii\/EK87C62XNH. Accessed June 16, 2025."},{"key":"2028_CR41","doi-asserted-by":"crossref","unstructured":"Rowley TK, McLaughlin AR, Cherry L, Fallah-Arani H, Ioannou F, Pyne Y, Shock D. A. Inhibitory effects of Dapirolizumab pegol, a monovalent anti-CD40L PEG-conjugated antigen-binding fragment lacking a functional Fc domain, on in vitro T follicular helper\/B cell interactions and cytokine production in systemic lupus erythematosus [abstract]. Arthritis Rheumatol. 2024;76 (suppl 9).","DOI":"10.1016\/j.ard.2025.06.358"},{"issue":"8","key":"2028_CR42","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1111\/ajt.15835","volume":"20","author":"D Liu","year":"2020","unstructured":"Liu D, Ford ML. CD11b is a novel alternate receptor for CD154 during alloimmunity. Am J Transpl. 2020;20(8):2216\u201325.","journal-title":"Am J Transpl"},{"key":"2028_CR43","doi-asserted-by":"publisher","first-page":"861471","DOI":"10.3389\/fimmu.2022.861471","volume":"13","author":"S Perrin","year":"2022","unstructured":"Perrin S, Magill M. The Inhibition of CD40\/CD154 Costimulatory Signaling in the Prevention of Renal Transplant Rejection in Nonhuman Primates: A Systematic Review and Meta Analysis. Front Immunol. 2022;13:861471.","journal-title":"Front Immunol"},{"issue":"3","key":"2028_CR44","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1124\/jpet.123.001771","volume":"387","author":"M Samant","year":"2023","unstructured":"Samant M, Ziemniak J, Paolini JF. First-in-human phase 1 randomized trial with the anti-CD40 monoclonal antibody kpl-404: safety, tolerability, receptor occupancy, and suppression of t-cell-dependent antibody response. J Pharmacol Exp Ther. 2023;387(3):306\u201314.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-026-02028-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-026-02028-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-026-02028-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T23:19:23Z","timestamp":1781565563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-026-02028-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2028"],"URL":"https:\/\/doi.org\/10.1007\/s10875-026-02028-8","relation":{},"ISSN":["1573-2592"],"issn-type":[{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol, associated documents, and informed consent forms were reviewed and approved by an institutional review board (Advarra). The study was conducted in accordance with the Declaration of Helsinki, the ethical principles of Good Clinical Practice Guidelines established by the International Council for Harmonisation, and all other applicable local regulatory requirements. Written informed consent was obtained from each participant prior to initiation of study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"S.L., B.L.D., and G.M.S. are employees of Tonix Pharmaceuticals and own stock and\/or have options in the company. N.H. is a consultant to Tonix Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}